Crossmark

Dual inhibition of FAS and HAS2/3 by 4-MU in Realgar-Coptis chinensis unveils a metabolic checkpoint for liver cancer therapy

Crossref DOI link: https://doi.org/10.1007/s13659-025-00540-9

Published Online: 2025-08-21

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Songtao https://orcid.org/0000-0001-9533-7295
Wang, Yingying

Deng, Denghui

Zheng, Guohua

Mei, Hanxiang

Wang, Cong

Zheng, Xiang

Gui, Chun

Liao, Fei

Xiang, Meixian
Funding

Funding for this research was provided by:

State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project of Traditional Chinese Medicine - Chinese Medicine Resource Science (Medicinal Mineralogy)

Open Fund of Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine and Hubei Provincial Department of Education Guiding Program (B2023089)

Natural Science Foundation of Hubei Province (2024AFD252)

Natural Science Foundation Project of Hubei Provincial Administration of Traditional Chinese Medicine (ZY2025D020)

Fundamental Research Funds for the Central Universities South-Central MinZu University (CZZ24017)
License Information

Text and Data Mining valid from 2025-08-21

Version of Record valid from 2025-08-21
More Information

Article History

Received: 29 May 2025

Accepted: 11 August 2025

First Online: 21 August 2025

Change Date: 14 December 2025

Change Type: Update

Change Details: The first affiliation and the funding information have been updated.

Declarations

:

: This experimental design was conducted and approved following the instructions of the institutional animal care and use committee of Ahram Canadian University (Approval number: REC2524). All animal experiments were conducted following the regulations of Directive 2010/63/EU in Europe, and this study is reported under ARRIVE guidelines ( ).

: Not applicable.

: All authors declare no competing financial interests.

Document is current

Any future updates will be listed below